Apimeds Pharmaceuticals US, Inc. Logo

Apimeds Pharmaceuticals US, Inc.

Biopharma developing non-narcotic bee venom therapies for osteoarthritis pain and inflammation.

APUS | US

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
United States of America
Address:
100 MATAWAN RD, 7747 MATAWAN
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Apimeds Pharmaceuticals US, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies to treat inflammation and pain. The company's lead program is Apitox, a novel, non-narcotic therapy derived from purified honey bee venom. Apitox is being clinically studied for treating pain and inflammation, particularly in patients with osteoarthritis. Apimeds operates on a principle it calls 'Actual Intelligence (ai²™),' which emphasizes human experience, scientific rigor, and clinical judgment to identify and develop overlooked or distressed clinical assets. This approach guides the company in navigating regulatory, intellectual property, and market access challenges, with a primary commitment to patients and physicians.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Apimeds Pharmaceuticals US, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Apimeds Pharmaceuticals US, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Apimeds Pharmaceuticals US, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Kolon TissueGene, Inc. Logo
Developing cell and gene therapies for orthopedic and degenerative disorders.
United States of America 950160
Develops animal health products and novel drugs for human cancer and autoimmune diseases.
South Korea 041960
KOREA ARLICO PHARM CO.,LTD. Logo
Manufactures generic drugs and provides CDMO services to a global market.
South Korea 260660
Develops and manufactures prescription (ETC) and over-the-counter (OTC) medicines for public health.
South Korea 014570
Korro Bio, Inc. Logo
A clinical-stage biopharma using RNA editing to develop medicines for rare & prevalent diseases.
United States of America KRRO
K Pharma,Inc. Logo
Develops iPS cell-based drugs and regenerative medicine for central nervous system disorders.
Japan 4896
Kringle Pharma,Inc. Logo
Develops regenerative HGF medicines for rare and intractable neurological diseases.
Japan 4884
Krka Logo
Develops and sells generic prescription, non-prescription, and animal health products globally.
Slovenia KRKG
Krystal Biotech, Inc. Logo
Developing redosable gene therapies for rare diseases using a modified HSV-1 vector.
United States of America KRYS
KUKJEON PHARMACEUTICAL Co.,Ltd Logo
A chemical solutions provider manufacturing Active Pharmaceutical Ingredients and electronic materials.
South Korea 307750

Talk to a Data Expert

Have a question? We'll get back to you promptly.